As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable.
Please note that following a request from the company, the timelines for this appraisal are to be revised in order that key additional data can be included in the company submission. Therefore, further information regarding the scheduling of this appraisal will be available in due course.